Antihypertensive and pleiotropic activity of the calcium antagonist amlodipine in patients with arterial hypertension and obesity

Cover Page

Cite item

Full Text

Abstract

The goal lies in the study of amlodipine effects on levels of blood pressure (BP), hypertensive reaction under isometric exercise, lipid and carbohydrate metabolism, platelet hemostasis, quality of life (QoL) and psychological status in patients with arterial hypertension (AH), obese abdominal type. Material and methods. The study included 30 patients with hypertension of the 1st and 2 nd degree in age from 37 to 72 years (mean age 56.6±7.9 years) with abdominal obesity type. After a 2-week period "cleanse" of patients, amlodipine was administered at an initial dose of 5 mg, with an increase up to 2 weeks in the absence of 10 mg of achieving target blood pressure (less than 140/90 mm Hg). The total duration of treatment took 6 weeks. In a study conducted, the clinical examination and ambulatory BP monitoring were also included, and a manual isometric test was taken, to determine the concentration of lipids and lipoproteins, glucose and insulin platelet aggregation (spontaneous and under the influence of adenosine acid) was evaluated, as well as adrenaline in different concentrations. The questionnaires on quality of life, Hospital Anxiety and Depression Scale were used as well. Results. Against the background of 6 weeks of therapy with amlodipine, a decrease in blood pressure levels, as measured by the patient in a sitting position (21.7±8.2/12.3±4.6 mm Hg, p<0.001) and in the standing position (19.8±6.9/11.5±5.5 mm Hg, p<0.001). Appointment of amlodipine to patients with hypertension obesity has led to positive changes in the diurnal blood pressure profile. This was combined with a decrease in the heart rate of the patient in the sitting position (at 4.2±6.4 beats / min, p=0.002) and standing (at 2.6±5.9 beats/min, p=0.03). After 6 weeks of receiving amlodipine at the peak of isometric exercise were detected decrease in average blood pressure levels (20.2±11.6/10.2±5.2 mm Hg, p<0.001), heart rate (at 4.2±6.6 beats / min, p=0.002) and the value of the "double work" (30.2%, p<0.05). In response to isometric exercise there was a decrease in diastolic blood pressure level of growth (6.9%, p=0.012) and the value of the "double work" (21.9%, p<0.05). The therapy with amlodipine was observed decrease in total cholesterol and low density lipoprotein cholesterol. The concentration of blood glucose and insulin therapy remained stable. There was a positive trend to a decrease in platelet aggregation under the action of adenosine. QoL in patients with hypertension and obesity was significantly improved after 6 weeks of receiving amlodipine. Conclusion. In patients with hypertension and obesity demonstrated high antihypertensive efficacy of amlodipine, including the conditions of isometric exercise, inducing hypertensive reaction.

About the authors

M. G Bubnova

State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

Email: mbubnova@gnicpm.ru
д-р мед. наук, проф., рук. отд. реабилитации и вторичной профилактики сочетанной патологии с лаб. профилактики атеросклероза и тромбоза ФГБУ ГНИЦ ПМ 101990, Russian Federation, Moscow, Petroverigsky per., d. 10, str. 3

D. M Aronov

State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

д-р мед. наук, проф., рук. лаб. кардиологической реабилитации ФГБУ ГНИЦ ПМ, засл. деят. науки РФ 101990, Russian Federation, Moscow, Petroverigsky per., d. 10, str. 3

I. V Kuznetsova

State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

зав. терапевтическим отд-нием ФГБУ ГНИЦ ПМ 101990, Russian Federation, Moscow, Petroverigsky per., d. 10, str. 3

V. A Vygodin

State Research Center for Preventive Medicine of the Ministry of Health of the Russian Federation

вед. науч. сотр. ФГБУ ГНИЦ ПМ 101990, Russian Federation, Moscow, Petroverigsky per., d. 10, str. 3

References

  1. Levy D, Larson M.G, Vasan R.S et al. The progression from hypertension to congestive heart failure. JAMA 1996; 275: 1557-62.
  2. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. от имени участников исследования ЭССЕ-РФ. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваск. терапия и профилактика. 2014; 14 (4): 4-14.
  3. Lawes C.M, Hoorn S.V, Rodgers A. Global burden of blood - pressure - related disease, 2001. Lancet 2008; 371 (Issue 9623): 1513-8.
  4. Falaschetti E, Chaudhury M, Mindell J et al. Continued Improvement in Hypertension Management in England: Results From the Health Survey for England 2006. Hypertension 2009; 53: 480-6.
  5. Vasan R.S, Larson M.G, Leip E.P et al. Assessment of frequency of progression to hypertension in non - hypertensive participants in the Framingham Heart Study: cohort study. Lancet 2001; 358: 1682-6.
  6. Mancia G, Fagard R, Narkiewicz K et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2013; 31 (7): 1281-357.
  7. Toyo-Oka T, Nayler W.G. Third generation calcium entry blocker. Blood Pressure 1996; 5: 206-8.
  8. Epstein M. Role of a third generation calcium antagonists in the management of hypertension. Drugs 1999; 57 (Suppl. 1): 1-10.
  9. Julius S. Sympathetic hyperactivity and coronary risk in hypertension. Hypertension 1993; 21: 886-93.
  10. Brook R.D, Julius S. Automatic imbalance, hypertension and cardiovascular risk. Am J Hypertens 2000; 13: 112s-22s.
  11. Esler M. The sympathetic system and hypertension. Am J Hypertens 2000; 13: 99s-105s.
  12. Метелица В.И. Справочник по клинической фармакологии сердечно - сосудистых лекарственных средств. М.: Медицинское информационное агентство, 2005.
  13. Blood Pressure Lowering Yreatment Trialists` Collaboration. Effects of ACE-inhibitors, calcium antagonists, and other bloodpressure - lowering drugs: results of prospectively designed overvieus of randomized trials. Lancet 2000; 356: 1949-54.
  14. Trenkwalder P, Regourd E, Kluth-Pepper B, Sauerbrey-Wullkof N. Amlodipine besylate versus candesartan cilexetil in hypertensive patients - office and self - measured blood pressure: a randomized, double - blind, comparative, multicenter trial. Clin Drug Investig 2005; 25 (9): 567-77.
  15. Аронов Д.М., Лупанов В.П. Функциональные пробы в кардиологии. М.: МЕД пресс - информ, 2002; с. 295.
  16. Minami J, Ishimitsu T, Kawano Y, Matsuoka H. Effects of amlodipine and nifedipine retard on autonomic nerve activity in hypertensive patients. Clin Exp Pharmacol Physiol 1998; 25 (7-8): 572-6.
  17. Siche J.P, Baguet J.P, Fagret D et al. Effects of amlodipine on baroreflex and sympathetic nervous system activity in mild - to - moderate hypertension. Am J Hypertens 2001; 14 (5 Pt 1): 424-8.
  18. Milovanovic B, Trifunovic D, Milicevic N et al. The significance of amlodipine on Autonomic Nervous System Adjustment (ANSA Method): A new approach in the treatment of hypertension. Srp Arh Celok Lek 2009; 137 (7-8): 371-8.
  19. Wilke N.A. Weight carrying handgrip exercise testing in men with coronary artery disease. Am J Cardiol 1989; 64: 736-40.
  20. Perez-Conzales J.F, Schiller N.B. Direct and noninvasive evaluation of the cardiovascular responses to isometric exercise. Circ Res 1981; 48 (Suppl. II): II138-II148.
  21. Kozlowski S, Brzezinska Z, Nasar K et al. Plasma catecholamines during sustained isometric exercise. Clin Sci 1973; 45: 723-31.
  22. Belardinelli R, Barstow J. Skeletal muscle oxygenation during constant work rate exercise. Med Sci Sports Exerc 1995; 27: 512-9.
  23. Petrofski J. The influence of body fat on isometric exercise performance. Ergometrics 1981; 24: 215-22.
  24. Ольбинская Л.И., Хапаев Б.А. Анализ профилей «двойного произведения» в оценке эффективности и безопасности антигипертензивных лекарств. Рос. кардиол. журн. 2000; 4 (24): 52-5.
  25. Hjemdahl P, Wallen N.H. Calcium antagonist treatment, sympathetic activity and platelet function. Eur Heart J 1997; 18 (Suppl. A): A36-A50.
  26. Аронов Д.М. Значение амлодипина (норваска) в кардиологии//CardioСоматика. 2014; 5 (2): 15-21.
  27. Zhang X, Kichuk M.R, Mital S et al. Amlodipine promotes kininmediated nitric oxide production in coronary vicrovessels of falling human hearts. Am J Cardiol 1999; 84: 27L-33L.
  28. Lee S.A, Choi H.M, Park H.J et al. Amlodipine and cardiovascular outcomes in hypertensive patients: meta - analysis comparing amlodipine - based versus other antihypertensive therapy. Korean J Intern Med 2014; 29 (3): 315-24.

Copyright (c) 2016 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies